The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

BACKGROUND: Preclinical and clinical data indicate that p53 expression might modulate the activity of the epidermal growth factor receptor (EGFR), influencing response/resistance to anti-EGFR monoclonal antibodies. However, the association between p53 status and clinical outcome has not been clarifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziranu, Pina, Lai, Eleonora, Schirripa, Marta, Puzzoni, Marco, Persano, Mara, Pretta, Andrea, Munari, Giada, Liscia, Nicole, Pusceddu, Valeria, Loupakis, Fotios, Demurtas, Laura, Libertini, Michela, Mariani, Stefano, Migliari, Marco, Dubois, Marco, Giampieri, Riccardo, Sotgiu, Giovanni, Dei Tos, Angelo Paolo, Lonardi, Sara, Zaniboni, Alberto, Fassan, Matteo, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266772/
https://www.ncbi.nlm.nih.gov/pubmed/33970400
http://dx.doi.org/10.1007/s11523-021-00816-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266772/
https://www.ncbi.nlm.nih.gov/pubmed/33970400
http://dx.doi.org/10.1007/s11523-021-00816-3

Ejemplares similares